May 18, 2022
1 min watch
Save
VIDEO: Study shows lower IOP, better vision with Iluvien implant in DME
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Michael A. Singer, MD, discusses phase 3 data from the PALADIN study.
Over time, patients with diabetic macular edema treated with the Iluvien implant (fluocinolone acetonide intravitreal implant 0.19 mg, Alimera Sciences) had less of an IOP increase than previous studies and better vision, Singer said.
Published by:
Sources/Disclosures
Collapse
Source:
Singer M. Paladin data DME. Presented at: Retina World Congress; May 12-15, 2022; Fort Lauderdale, Fla.
Disclosures:
Singer reports being a paid consultant to Alimera Sciences.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.